Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

Inclusion Criteria

• •Histologically confirmed squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
• •* Stage IVB, recurrent, or persistent disease
• •Not amenable to curative surgery and/or radiotherapy
• •At least 1 unidimensionally measurable lesion
• •* At least 20 mm by palpation, plain x-ray, CT scan, or MRI OR at least 10 mm by spiral CT scan
• •* Biopsy confirmation required if lesion is less than 30 mm
• •* Target lesion must be outside of a previously irradiated field
• •No craniospinal metastases
• •Performance status - GOG 0-1
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Bilirubin no greater than 1.5 times normal
• •Alkaline phosphatase no greater than 3 times normal
• •AST no greater than 3 times normal
• •Creatinine ≤ 1.2 mg/dL
• •Creatinine \> 1.2 mg/dL but \< 1.5 mg/dL AND creatinine clearance ≥ 50 mL/min
• •No bilateral hydronephrosis not alleviated by ureteral stents or percutaneous drainage
• •Not pregnant or nursing
• •Fertile patients must use effective contraception
• •No prior or concurrent malignancy within the past 5 years except nonmelanoma skin cancer
• •No prior malignancy whose treatment contraindicates the current study therapy
• •No concurrent clinically significant infection
• •No concurrent cytokines
• •At least 6 weeks since prior chemoradiotherapy and recovered
• •No prior chemotherapy (except when concurrently administered with radiotherapy)
• •At least 3 weeks since prior radiotherapy and recovered
• •Recovered from prior surgery